Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) Shares Outstanding (Diluted Average): 2021-2025

Historic Shares Outstanding (Diluted Average) for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to $72.6 million.

  • C4 Therapeutics' Shares Outstanding (Diluted Average) rose 4.22% to $72.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.6 million, marking a year-over-year increase of 4.22%. This contributed to the annual value of $69.4 million for FY2024, which is 39.75% up from last year.
  • As of Q3 2025, C4 Therapeutics' Shares Outstanding (Diluted Average) stood at $72.6 million, which was up 2.19% from $71.0 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $72.6 million in Q3 2025 and a low of $43.9 million during Q2 2021.
  • Over the past 3 years, C4 Therapeutics' median Shares Outstanding (Diluted Average) value was $68.8 million (recorded in 2024), while the average stood at $62.5 million.
  • Data for C4 Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY surged of 41.48% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows C4 Therapeutics' Shares Outstanding (Diluted Average) stood at $46.0 million in 2021, then climbed by 6.12% to $48.9 million in 2022, then grew by 1.59% to $49.6 million in 2023, then spiked by 39.75% to $69.4 million in 2024, then rose by 4.22% to $72.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $72.6 million for Q3 2025, versus $71.0 million for Q2 2025 and $70.8 million for Q1 2025.